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Background: Several clinical trials have demonstrated the safety
and effectiveness of oral tenofovir disoproxil fumarate (TDF), with or
without emtricitabine (FTC), as pre-exposure prophylaxis (PrEP) for
reducing the risk of HIV acquisition. Adherence to the study product
was insufficient to demonstrate the effectiveness of FTC/TDF in 2
PrEP clinical trials conducted among women (FEM-PrEP and the
Vaginal and Oral Interventions to Control the Epidemic study), but
further analyses of adherence in these studies may inform PrEP
demonstration projects and future HIV prevention clinical trials.
Methods: We randomly selected a subcohort of 150 participants
randomized to FTC/TDF in 3 FEM-PrEP sites (Bondo, Kenya;
Bloemfontein, South Africa; and Pretoria, South Africa) to examine
adherence levels over time and to assess factors associated with
adherence, based on plasma tenofovir and intracellular tenofovir
diphosphate drug concentrations in specimens collected at 4-week
visit intervals.
Results: We observed drug concentrations consistent with good
adherence in 28.5% of all visit intervals when drug was available to
use, but only 12% of participants achieved good adherence
throughout their study participation. In multivariate analysis, the
Bloemfontein site [odds ratio (OR): 2.43; 95% confidence interval
(CI): 1.32 to 4.48] and liking the pill color (OR: 2.93; 95% CI: 1.18
to 7.27) were positively associated with good adherence, whereas
using oral contraceptive pills at enrollment was negatively associated
with good adherence (OR: 0.37; 95% CI: 0.18 to 0.74).
Conclusions: Most participants did not regularly adhere to the
study product throughout their trial participation, although a small-
minority did. Few factors associated with good adherence to the
study product were identified in FEM-PrEP.
Key Words: pre-exposure prophylaxis, FEM-PrEP, adherence,
women, Africa
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INTRODUCTION
Numerous randomized clinical trials have assessed the
safety and effectiveness of oral tenofovir disoproxil fumarate
(TDF), with or without emtricitabine (FTC), as pre-exposure
prophylaxis (PrEP) for reducing the risk of HIV acquisition.
Recently, oral TDF was found effective for preventing HIV
among people who inject drugs.1 Oral FTC/TDF had already
been shown to reduce HIV acquisition among HIV-uninfected
partners in serodiscordant couples,2 heterosexual men and
women,3 and transgender women and men who have sex with
men.4 However, 2 trials conducted among women, FEM-PrEP
and the Vaginal and Oral Interventions to Control the Epidemic
(VOICE) study, were unable to demonstrate the effectiveness
of oral FTC/TDF (FEM-PrEP and VOICE) or oral TDF alone
(VOICE) because of low adherence to the study product.5,6
In HIV prevention clinical trials, healthy volunteers were
asked to adhere to an investigational product that may or may
not prevent HIV acquisition and, moreover, may be a placebo.
Consequently, the adherence patterns and factors associated
with adherence to the study product within a placebo-
controlled PrEP trial may or may not be similar to the patterns
and factors influencing adherence to a marketed efficacious
product outside the clinical trial context. Nonetheless, a better
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understanding of adherence and nonadherence within a trial
may help in developing approaches for supporting participant
adherence in PrEP demonstration projects and in future trials of
new HIV prevention technologies.
Several factors have previously been shown to be
associated with low adherence to the study product in PrEP
clinical trials. In Partners PrEP, depending on the measure used,
these factors were younger age, heavy alcohol use, sexual
behavior, and months on study product.7 In VOICE, young
single participants had lower adherence than older married par-
ticipants.6 Adherence to the study product was measured using
pill counts, drug concentrations, and electronic pill bottle mon-
itoring in Partners PrEP2,7 and by drug concentrations in
VOICE.6 In FEM-PrEP, a preliminary case–control analysis
among 124 participants randomized to FTC/TDF (33 who se-
roconverted and 91 matched HIV-negative controls) found that
adherence was low in the majority of participants. Among the
HIV-uninfected controls, 24% had evidence of recent pill use
($10 ng/mL tenofovir in plasma) at 2 consecutive visits
matched to the infection window of participants who serocon-
verted.5 For this article, we measured adherence in a larger
prospective subcohort of participants selected for analysis of
drug concentrations to assess the association between baseline,
time-dependent, and poststudy factors and drug concentrations
consistent with good levels of adherence, and to describe pat-
terns of adherence over time.
METHODS
Overview of the FEM-PrEP Clinical Trial
Initiated in 2009, FEM-PrEP was a phase 3, random-
ized, double-blind, placebo-controlled trial to assess the
safety and effectiveness of once-daily oral FTC/TDF for the
prevention of HIV in women at higher risk of HIV in Bondo,
Kenya; Bloemfontein and Pretoria, South Africa; and Arusha,
Tanzania. At screening, women were considered to be at
“higher risk” if they had had sex at least once within the past
2 weeks or had had sex with more than 1 sexual partner in the
past month. The primary effectiveness and safety results,
including a description of the overall study population, have
been previously published.5 In brief, participants were ran-
domized to either once-daily FTC/TDF or placebo. They were
asked to use the study product for 52 weeks and attend study
visits every 4 weeks. The study visits included HIV testing,
adherence counseling,8 safety assessments, free contraceptive
counseling and method provision (contraceptive use at enroll-
ment was an eligibility requirement), provision of study prod-
uct, and HIV risk reduction services including counseling,
free condoms, and treatment of curable sexually transmitted
infections (STIs). A total of 2120 participants were enrolled,
and 82% completed the study.5 All associated ethics and
regulatory committees approved the trial, and all participants
provided written informed consent. The trial closed early in
April 2011 because of a lack of effect.9
Data Collection
We used data collected from face-to-face quantitative
questionnaires about (1) demographics at screening, (2) HIV
risk perceptions at enrollment, (3) sexual partners and sexual
behaviors at enrollment and at quarterly visits, and (4) study
product acceptability and perception of study product assign-
ment at the time of permanent product withdrawal. We also
used data on adverse events, on STI test results at screening,
and from blood samples collected at each study visit through
52 weeks. We chose to use drug concentrations as the
measure of adherence rather than self-reported adherence
and pill counts because we have previously documented that
adherence was strongly overestimated when those measures
were used.10
Sample Selection and Analysis of
Drug Concentrations
After the trial, we randomly selected 50 participants
who were assigned FTC/TDF and who attended at least 1
follow-up visit from each of the sites where HIV infections
occurred (Bloemfontein, Bondo, and Pretoria). No partic-
ipants in the Arusha site contributed more than 16 weeks of
follow-up data, and none seroconverted; therefore, we did not
include participants from Arusha in this analysis. The
resulting subcohort of 150 participants was scheduled to
make 1364 visits between weeks 4 and 52 of follow-up
(accounting for the early closure of the trial), of which, 55
visits (4.0%) were missed. We further excluded 122 visits
(8.9%) when the participant did not have study product
available to use (eg, because of protocol-required product
interruption), 24 visits (1.8%) where no or insufficient
specimen was available for the analysis of drug concentra-
tions, and 2 visits (0.1%) when the visit interval was less than
10 days long. Specimens from the remaining 1161 visit
intervals (7.8 per participant) were included in our analysis;
the mean length of these visit intervals was 27.9 days with
a range of 15–39 days. The final sample size provided at least
80% power to detect a doubling in the odds of good adher-
ence based on reasonable assumptions about the overall pro-
portion of visit intervals with good adherence, the proportions
of participants with a given characteristic, and the correlation
among repeated measures.
Concentrations of tenofovir (TFV) in plasma were used
to characterize recent pill use (ie, within the previous 10
days). Because of its longer half-life, intracellular tenofovir
diphosphate (TFV-DP) can be used to assess adherence over
longer periods.11 Although FEM-PrEP did not collect periph-
eral blood mononuclear cells for this purpose, we were able to
use a novel and validated assay to assess TFV-DP in upper
layer packed cells (ULPCs; consisting primarily of platelets,
lymphoctyes, monocytes, and granulocytes) from specimens
that were collected at each visit for a different purpose (ret-
rospective detection of HIV PCR-DNA if the participant
seroconverted).12
In consultation with the study pharmacologist, the TFV
in plasma and intracellular TFV-DP concentration data were
used to develop a semi-ordinal composite adherence score for
each 4-week visit interval. Scores ranged from 0 (no detectable
TFV and ,10,000 fmol/mL TFV-DP, consistent with low or
no doses of drug in the interval) to 5 (.10 ng/mL TFV in
plasma and .1,000,000 fmol/mL TFV-DP, consistent with
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taking the product nearly every day) (Table 1). Good adher-
ence (scores 4 or 5) was defined as having TFV in plasma
exceeding 10 ng/mL and intracellular TFV-DP in ULPCs
exceeding 100,000 fmol/mL; a participant taking study drug
4 or more times each week over the preceding 28 days was
expected to exhibit drug concentrations in these ranges.
Statistical Methods
We performed logistic regression to assess associations
between baseline, time-dependent, and poststudy factors and
good adherence in each 4-week interval using robust variance
estimation to account for repeated measures on participants.
Bivariate analyses were conducted, followed by multivariate
analysis that included factors significantly associated (P ,
0.05) with good adherence in the bivariate analyses. The final
model was simplified using stepwise variable selection.
The prespecified factors that we hypothesized might be
associated with adherence were included in the analysis.
Baseline variables included site, age, education, marital status,
living with partner, perception of HIV risk in the next 4 weeks,
using effective contraception at screening, using oral contra-
ceptive pills (OCPs) at enrollment, and having an STI or
bacterial vaginosis on or before enrollment. Time-dependent
variables included having missed a previous visit, type of
partner(s) in the previous 4 weeks, having had sex without
using a condom in the previous 4 weeks, knowledge of partner
having HIV, having had a gastrointestinal event, and time in
study. The poststudy variables we assessed were participants’
beliefs about their randomization arm and pill attributes.
RESULTS
Demographics and Baseline Characteristics
Within our subcohort, participants in the 2 South African
sites (Bloemfontein and Pretoria) had similar demographic and
other baseline characteristics, although these characteristics
differed from those of participants in Kenya (Bondo) (Table 2).
Participants from Bloemfontein and Pretoria were younger
(72% and 66%, respectively, ages: 18–24 years) than partic-
ipants from Bondo (38%, ages: 18–24) and had more years of
education (mean, 11.7 years in both Bloemfontein and Pretoria
versus 8.6 years in Bondo). Marital status and number of sex-
ual partners also differed: 74% of participants in Bondo and
4% of participants in both South African sites were married,
and 49% of participants in Bondo versus 8% in Bloemfontein
and 16% in Pretoria reported having more than 1 sexual partner
at baseline. In addition, more participants in Bondo (56%) than
in Bloemfontein (28%) and Pretoria (30%) were unsure
whether any of their sexual partners had HIV. Similar propor-
tions of participants in Pretoria (70%) and Bondo (74%) re-
ported that they had had sex without using a condom at least
once in the past 4 weeks with any sexual partner compared
with a smaller proportion of participants in Bloemfontein
(46%). Fewer participants in Bondo (22%) than in Bloemfon-
tein (30%) and Pretoria (42%) reported using OCPs at enroll-
ment to fulfill their contraceptive use requirement for
participating in the study.
Poststudy Variables
At the end of the trial, the majority of participants from
all the 3 sites (55% in Bloemfontein, 53% in Pretoria, and 93%
in Bondo) said that they did not know whether they were
randomized to FTC/TDF or placebo. Among those participants
in Bloemfontein (n = 21) and Pretoria (n = 22) who did pos-
tulate their randomization assignment, 77% correctly guessed
that that they had been assigned FTC/TDF (Table 2). Almost all
participants in Bondo (98%) and most participants in Bloem-
fontein and Pretoria (87% and 75%, respectively) reported lik-
ing the color of the study product, and fewer participants in
Pretoria (57%) than in Bondo and Bloemfontein (both 83%)
reported liking the size of the study product.
Overall Visit Interval Adherence
Fewer than 50 participants in the subcohort contributed
52 weeks of data because of early closure of the trial. Despite
the availability of drug, 43.4% of all observed visit intervals
had a composite adherence score of 0 (Table 3), and we
observed only 28.5% of all visit intervals in the 2 highest
composite adherence categories. There was also little evi-
dence of participants exclusively taking drug in the day or
2 before clinic visits to give the appearance of adhering, also
referred to as “white coat adherence.” Of the 553 visit inter-
vals with nonquantifiable concentrations of TFV-DP
(,10,000 fmol/mL) and thus little or no long-term use, only
31 (5.6%) had TFV plasma concentrations consistent with pill
taking in the 2 days before the visit ($10 ng/mL). Similarly,
in the majority of visit intervals demonstrating recent pill use
(TFV concentrations of $10 ng/mL), the intracellular
TABLE 1. Qualitative Adherence Composite Scores, Corresponding TFV and TFV-DP Concentrations, and Estimated Doses per
Interval
Adherence
Composite Score TFV in Plasma and TFV-DP in Upper Layer Packed Cells Estimated Doses per Interval
0 No detectable TFV and ,10,000 fmol/mL TFV-DP A low number of doses or no doses at all in the interval
1 Detectable TFV but ,10,000 fmol/mL TFV-DP A few doses in the entire interval
2 10,000–100,000 fmol/mL TFV-DP, regardless of TFV 1–2 doses per week
3 ,10 ng/mL TFV and .100,000 fmol/mL TFV-DP Several doses early in the interval, followed by a stop in
the week or 2 leading up to the sampling visit
4 .10 ng/mL TFV and 100,000–1,000,000 fmol/mL TFV-DP 4–5 doses per week
5 .10 ng/mL TFV and .1,000,000 fmol/mL TFV-DP Approximately daily dosing
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TFV-DP concentrations ($100,000 fmol/mL) were consistent
with using the study product fairly regularly throughout the
interval (Table 3).
Patterns of Adherence Over Time
Figure 1 displays the frequencies of adherence scores
by scheduled follow-up visit among participants in the sub-
cohort who had the study product available for use during the
visit interval. The use of study product seemed to decrease
over time, with 35% of participants having good adherence
(scores 4 and 5) at week 4 compared with 23% having good
adherence at week 52. Conversely, nonuse of the study
product (a score of 0) generally increased over time.
Figure 1 also shows the frequencies of adherence scores
by site. Participants from the 2 South Africa sites seemed to












Mean 23.3 22.1 26.3 23.9
Median (range) 21.5 (18–35) 21.0 (18–32) 25.5 (18–35) 23.0 (18–35)
18–24 33 (66) 36 (72) 19 (38) 88 (59)
25–29 13 (26) 13 (26) 15 (30) 41 (27)
.30 4 (8) 1 (2) 16 (32) 21 (14)
Education, yr
Mean 11.7 11.7 8.6 10.7
Median (range) 12.0 (7–18) 12.0 (5–15) 8.0 (0–14) 12.0 (0–18)
0–9 5 (10) 2 (4) 33 (66) 40 (27)
$10 45 (90) 48 (96) 17 (34) 110 (73)
Married 2 (4) 2 (4) 37 (74) 41 (27)
Living with partner 7 (14) 8 (16) 34 (68) 49 (33)
Risk perception
No chance 30 (60) 37 (74) 11 (22) 78 (52)
Some chance (small, moderate, high) 20 (40) 13 (26) 39 (78) 72 (48)
Effective contraception use at screening† 26 (52) 24 (48) 34 (68) 84 (56)
Oral contraceptive pill use at enrollment 21 (42) 15 (30) 11 (22) 47 (31)
Sexually transmitted infections‡§ 12 (25) 12 (30) 4 (9) 28 (21)
Bacterial vaginosis§ 29 (60) 11 (28) 15 (35) 55 (42)
Time-dependent variables (as reported at baseline)
Had more than 1 partner 8 (16) 4 (8) 24 (49) 36 (24)
Had vaginal or anal sex without a condom in past 4
weeks (with primary or other partner)
35 (70) 23 (46) 37 (74) 95 (63)
Knowledge of any partner (primary or other) having
HIV
Yes 1 (2) 0 (0) 0 (0) 1 (0)
No 34 (68) 36 (72) 22 (44) 92 (61)
Do not know 15 (30) 14 (28) 28 (56) 57 (38)
Poststudy variablesk
Randomization arm belief
Placebo 5 (11) 5 (11) 2 (5) 12 (9)
FTC/TDF 17 (36) 16 (34) 1 (2) 34 (25)
Do not know 25 (53) 26 (55) 39 (93) 90 (66)
Pill attributes¶
Liked size 27 (57) 39 (83) 35 (83) 101 (74)
Liked color 35 (75) 41 (87) 41 (98) 117 (86)
Liked taste 37 (79) 38 (81) 39 (93) 114 (84)
Liked daily pill taking 38 (81) 44 (94) 41 (98) 123 (90)
*Data presented are mean, median (range), or n (%).
†Oral contraceptive pills, injectable, sterilization, implant, intrauterine device.
‡Syphilis, chlamydia, gonorrhea, trichomoniasis.
§Among participants who were tested.
║47, 47, and 42 participants, respectively, provided responses to poststudy variables in Bloemfontein, Pretoria, and Bondo.
¶Four-response Likert scale (do not like at all, do not like, liked, liked a lot).
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have the greatest variability in study product adherence,
although participants in Bloemfontein contributed the least
amount of follow-up data. Bondo had the highest percentage
of participants with no evidence of study product use over time.
At the individual level, 83 participants (55%) had at
least 1 study interval with drug concentrations consistent with
good adherence. However, throughout their trial participation,
only 18 participants (12%) had drug concentrations consistent
with good adherence (scores 4 and 5; none of whom
contributed a full 52 weeks of follow-up before study
closure), 34 (23%) consistently had no or low drug concen-
trations (scores 0 and 1), 8 (5%) had intermittent but non-zero
adherence over time (scores 2 or 3), and the majority (n = 90;
60%) had drug concentrations that generally fluctuated across
all adherence scores.
Factors Associated With Adherence
In bivariate analyses, we found that being from the
Bloemfontein site [odds ratio (OR): 2.31; 95% confidence
interval (CI): 1.25 to 4.26 when pooling data from the other
sites], liking the color of the pill (OR: 3.09; 95% CI: 1.30 to
7.35) and liking the size of the pill (OR: 2.10; 95% CI: 1.03 to
4.31) were significantly associated with good adherence
(Table 4). We also found that using OCPs at enrollment
(OR: 0.37; 95% CI: 0.20 to 0.70) and reporting having had
sex without using a condom in the 4-week interval before drug
measurement (OR: 0.60; 95% CI: 0.37 to 0.98) were negatively
associated with good adherence. We saw a trend toward
decreased adherence over time, but this was not significant in
bivariate analysis (OR: 0.99 per week in study; 95% CI: 0.98 to
1.00). In multivariate analysis, being from the Bloemfontein
site (OR: 2.43; 95% CI: 1.32 to 4.48) and liking the color of the
pill (OR: 2.93; 95% CI: 1.18 to 7.27) remained positively
associated with good adherence and using OCPs at enrollment
remained negatively associated with good adherence (OR:
0.37; 95% CI: 0.18 to 0.74) (Table 4).
DISCUSSION
Overall adherence among the prospective subcohort
described here was similar to the adherence levels we
previously reported from a preliminary case–control analy-
sis5; the majority of participants did not regularly take their
study product, if they took it at all. Our findings suggest that
a considerable minority of participants (23% of our subco-
hort) may have joined FEM-PrEP without ever intending to
take the study product because their drug concentrations start-
ing at week 4 showed that they rarely, if ever, took drug.
Although 55% of participants had at least 1 visit interval
TABLE 3. Adherence Composite Scores, Listed by Plasma TFV and Intracellular TFV-DP Concentrations and by Participant Visit
Intervals
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consistent with good adherence when drug was available to
use, only a small minority of the subcohort participants—12%
across all the 3 sites—seemed to regularly take the study
product for the length of trial participation. It is plausible that
these participants joined FEM-PrEP with the intent to adhere
as instructed and maintained their interest and motivation
throughout their time in the trial. Adherence among the
majority of participants (60%), however, fluctuated substan-
tially over time, suggesting that there could be factors that
influenced adherence at different time points during the trial.
Our findings also suggest that “white coat adherence,” where
participants take their study pills in advance of their study
visits to seem adherent, was not common.
We found few factors associated with good study
product adherence. Before the drug concentration data were
available, we had hypothesized that adherence among
participants who were already using effective contraception
at screening would be somewhat higher (compared with
participants initiating contraception because of trial eligibility
criteria) because they had already shown the willingness and
ability to adopt preventive health behaviors.13 However, we
did not confirm such an effect. We did find that participants
who chose OCPs as their contraceptive at enrollment (regard-
less of previous contraceptive method use), and hence were
asked to take 2 pills daily as part of the study, were much less
likely to adhere than participants who chose another contra-
ceptive method. It is unknown whether participants who
opted to use OCPs differed in other unmeasured factors that
would have affected adherence (irrespective of OCP use), if
the request to take 2 daily pills led to poor adherence, or
a combination of both. Nonetheless, this observation may
have programmatic implications and should be assessed in
demonstration projects. Furthermore, we found no association
between perceived HIV risk measured only at enrollment and
good adherence throughout the trial, which may be partly due
to how HIV risk perception was measured (ie, perception of
risk in the subsequent 4 weeks). Additional secondary analy-
ses of contraception and risk perceptions are underway and
may shed further light on the relationship between these fac-
tors and adherence.
It is unclear why participants from Bloemfontein had
better adherence. They contributed less time before study
FIGURE 1. Adherence score frequencies by scheduled follow-up visit.
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closure, but their adherence was also generally better in the
first few months of follow-up than in the other sites. It is
possible that unmeasured or as-yet unidentified individual
factors, such as alcohol use or concerns about taking an
investigational drug, or the broader social context, such as
varying community support for clinical trials or the clinic
environment, influenced adherence and differed across sites.
We excluded data from visit intervals where drug was
not available to use (eg, because of missed product supply
visits or protocol-defined product withdrawals) because includ-
ing those results would have masked adherence relationships of
interest. We also did not impute drug concentration data that
were missing when participants missed the next visit after
receiving the study product. Although the latter missing data
could have introduced some bias, we did not find any evidence
that missing study visits were associated with greater or lesser
adherence in ensuing intervals when product was available.
Another potential limitation of our analyses was that we were
not able to develop a strictly ordinal score relating overall
adherence in 4-week intervals to drug concentrations. TFV in
plasma concentrations and TFV-DP in ULPCs reflect adher-
ence during different portions of the visit interval, and different
patterns of adherence could lead to similar drug concentrations
when measured only once every 28 days. Hence, we chose to
model factors associated with good adherence, which was
reasonably well defined using available drug concentration
data. Moreover, most visit intervals (76.1%) were consistent
with either very poor or good adherence, suggesting that
a dichotomized outcome based on the higher adherence
concentrations targeted in the protocol was appropriate.
Our overall adherence results are similar to the adherence
findings in VOICE, in which fewer than 33% of samples from
TABLE 4. Bivariate and Multivariate Regression of Factors Associated With Good Adherence
Factor* Bivariate OR (95% CI) P Multivariate OR (95% CI) P
Baseline variables
Age†
25–29 1.82 (0.95 to 3.48) 0.159 — —
$30 1.72 (0.76 to 3.86) — — —
Years of education‡ 0.71 (0.38 to 1.31) 0.271 — —
Married 1.02 (0.54 to 1.93) 0.956 — —
Living with partner 1.32 (0.73 to 2.41) 0.360 — —
Risk perception§ 1.38 (0.77 to 2.46) 0.279 — —
Using effective contraceptionk at screening 0.64 (0.36 to 1.15) 0.137 — —
Using OCP at enrollment 0.37 (0.20 to 0.70) 0.002 0.37 (0.18 to 0.74) 0.005
Diagnosed STI¶ 0.67 (0.35 to 1.29) 0.232 — —
Diagnosed bacterial vaginosis 0.63 (0.34 to 1.17) 0.145 — —
Study site: Bloemfontein# 2.31 (1.25 to 4.26) 0.007 2.43 (1.32 to 4.48) 0.004
Time-dependent variables
Missed previous visit 0.81 (0.33 to 2.00) 0.648 — —
Partner type in previous 4 weeks** 1.04 (0.56 to 1.96) 0.893 — —
Sex without condom in previous 4 weeks†† 0.60 (0.37 to 0.98) 0.043 — —
Knowledge that partner has HIV‡‡ 0.92 (0.54 to 1.58) 0.769 — —
Gastrointestinal event§§ 1.77 (0.62 to 5.06) 0.288 — —
Time in study 0.99 (0.98 to 1.00) 0.084 — —
Poststudy variables —
Randomization arm beliefkk 0.896 — —
FTC/TDF 1.26 (0.33 to 4.80) — — —
Do not know 1.33 (0.38 to 4.70) — — —
Pill attributes — —
Liked size 2.10 (1.03 to 4.31) 0.043 — —
Liked color 3.09 (1.30 to 7.35) 0.011 2.93 (1.18 to 7.27) 0.020
Liked taste 1.71 (0.80 to 3.67) 0.166 — —
Liked daily pill-taking 0.95 (0.47 to 1.94) 0.889 — —
*Response is “yes” versus “no” unless specified.
†Age between 18 and 24 as reference.
‡$10 versus 0–9 years.
§No chance versus some chance (small, moderate, high).
kOral contraceptive pills, injectable, sterilization, implant, intrauterine device.
¶Syphilis, chlamydia, gonorrhea, trichomoniasis.
#Data from Bondo and Pretoria were pooled.
**More than 1 sex partner versus primary partner only.
††Vaginal or anal sex; primary or other partner.
‡‡Primary or other partner; yes or do not know/do not want to answer versus no.
§§Nausea, vomiting, or diarrhea with onset date 3 or more days before drug level test visit.
kkPlacebo as reference.
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a random sample of participants assigned to FTC/TDF showed
evidence of TFV at quarterly visits.6 We did not, however, find
any association between younger unmarried participants and
lower adherence to the study product, as demonstrated in
VOICE.6 This may be because the 2 studies used different meth-
ods to measure adherence (from results currently available,
VOICE assessed factors associated with a detectable TFV plasma
concentration of $0.3 ng/mL and also included samples when
participants had missed their previous visit) or because of differ-
ences in the study populations.
Moving forward, it will be crucial to continue focusing
on the development and evaluation of new methods to
enhance adherence counseling and other participant support
for achieving and maintaining good adherence in trials of
HIV prevention technologies and PrEP demonstration proj-
ects. The low adherence demonstrated in FEM-PrEP and
VOICE also provides evidence in support of investigator
review of aggregated drug concentration data throughout trial
implementation to ensure that participants assigned to the
study drug are actually taking it, rather than relying on self-
reported measures to assess adherence during the trial. This is
being performed in some ongoing HIV prevention clinical
trials and demonstration projects.
In summary, we found that only a small minority of
FEM-PrEP participants regularly adhered to the study
product. In interpreting these results, we must recognize that
participants were asked to adhere to the daily use of either an
investigational HIV prevention drug or a placebo. FEM-PrEP
participants were reminded at each study visit that the purpose
of the research was to determine whether FTC/TDF was
effective for HIV prevention. They were also counseled at
each study visit to use HIV risk reduction methods of known
effectiveness, such as condoms and partner reduction,
because it was not known whether FTC/TDF could prevent
HIV acquisition and because they may have been randomized
to the placebo, which could not protect against HIV.
Ultimately, taking a daily pill for HIV prevention may
not be feasible or acceptable for some African women at high
risk of HIV, but we cannot eliminate this option based solely
on inconsistent evidence from clinical trials assessing the
effectiveness of PrEP. Demonstration projects are planned or
under way, in which all participants are provided FTC/TDF,
now that it is a proven efficacious drug for reducing the risk
of HIV acquisition through sex, and are counseled on the
importance of adherence. The data from these projects will
allow for a better assessment of the role of daily oral
antiretroviral drugs for PrEP, particularly among African
women at high risk of HIV.
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